Drug Profile
Rimacalib
Alternative Names: SM-114; SMP 114Latest Information Update: 27 Feb 2015
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer Sumitomo Dainippon Pharma
- Class Disease-modifying antirheumatics; Small molecules
- Mechanism of Action Dinoprostone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 04 Aug 2006 This compound is still in active development
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
- 07 Sep 2004 Phase-II clinical trials in Rheumatoid arthritis in Japan (PO)